Replies to post #206654 on Biotech Values

[DewDiligence]

Reuters' saying that Gazyva/Treanda vs Rituxan/Treanda raised 3-year survival from 92% to "only" 94% makes the benefit sound trifling, but it's actually a 25% reduction in the risk of death during the first three years.